The developers of the innovative new drug Enhertu (trastuzumab deruxtecan) have recently ended price negotiations with the National Health Insurance Service (NHIS) to receive reimbursement as early as next month.On Monday, the NHIS announced the settlement of Enhertu’s price bargaining by updating i
After the government announced it would stop providing free Covid-19 drugs and start charging for them in the first half of this year, concerns are growing about a treatment gap due to delays in discussing the reimbursement of related medications.According to the Korea Disease Control and Prevention
The Korean Society for the Study of Obesity (KSSO) is now busy revising its guidelines ahead of Novo Nordisk's anticipated domestic launch of its obesity treatment Wegovy (semaglutide) late this year.According to a recent seminar of the Guidelines Committee at the KSSO’s 59th spring conference, the
"Korea is known for its successful clinical trials. However, underneath it is Korea’s characteristics of frequently delayed reimbursement for new drugs. I think part of it is to ensure access to new drugs by participating in clinical trials."Ingrid A. Mayer, vice president of global clinical strateg
The second-generation bruton tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), developed by BeiGene, has cleared the threshold of the Pharmaceutical Reimbursement Evaluation Committee (PREC) after a second attempt at expanded coverage.At the same meeting, AstraZeneca's asthma drug Fasenra (be
The 10th Cancer Disease Review Committee (CDRC), under the Health Insurance Review and Assessment Service (HIRA), held its first meeting with newly reconstituted members on Wednesday, during which it discussed nine new and expanded reimbursement proposals.However, most drugs did not pass the review,
Patients and the pharmaceutical industry pay keen attention to whether the government will reimburse Enhertu (trastuzumab deruxtecan), for which drug price negotiations are underway with the National Health Insurance Service (NHIS) from April.Patient organizations have been pressuring the government
MSD's 15-valent pneumococcal conjugate vaccine (PCV), Vaxneuvance, will be used in Korea in earnest next month as part of the government’s pediatric national immunization program (NIP).MSD Korea said it had secured sufficient batches of Vaxneuvance to prepare for its full-scale launch.Vaxneuvance is
PARP (poly ADP-ribose polymerase) inhibitors have recently emerged as a new treatment option for metastatic castration-resistant prostate cancer (mCRPC) with a poor prognosis and are expected to contribute significantly to improving survival rates.However, they remain far beyond the reach of most Ko
Starting next month, biliary tract cancer patients can add the anti-PD-L1 immunotherapy Imfinzi (durvalumab) at their own expense to the existing gemcitabine/cisplatin (GemCis) chemotherapy regimen for the first-line treatment of locally progressive or metastatic biliary tract cancer.It was part of
The first FGFR inhibitor for bladder cancer, Balversa (erdafitinib), will soon be launched in Korea.According to industry sources on Monday, Janssen Korea is gearing up to release Balversa without reimbursement in late March.Balversa is an FGFR (fibroblast growth factor receptor) inhibitor approved
Janssen has been delaying the Korean launch of its FGFR (fibroblast growth factor receptor) inhibitor Balversa (erdafitinib) for over a year, making many watchers wonder what's happening.Janssen received approval for Balversa on Nov. 24, 2022, from the Ministry of Food and Drug Safety (MFDS).Balvers
GSK's shingles vaccine Shingrix is associated with an increased risk of herpes zoster ophthalmicus (HZO) recurrence, suggesting that patients with a history of the disease should be monitored closely after vaccination, a new study said.Last Thursday, local time, researchers from the University of Ca
Gilead's HIV treatment and prevention drug Truvada (emtricitabine/tenofovir disoproxil fumarate) has survived after a series of twists and turns in the Korean market.According to the minutes of the Central Pharmaceutical Deliberation Committee (CPDC) meeting released by the Ministry of Food and Drug
New drugs with different mechanisms of action have recently entered the ulcerative colitis (UC) treatment market in Korea, heralding fierce competition.Last Friday, the Ministry of Food and Drug Safety (MFDS) approved Lilly's interleukin-23 (IL-23) inhibitor Omvoh (mirikizumab), giving Korean patien
Tevimbra (tislelizumab), an anti-PD-1 immunotherapy developed by BeiGene, has begun the process of seeking reimbursement in Korea.BeiGene's stance of supplying innovative new drugs at reasonable prices is drawing attention to whether it could alleviate the growing financial burden caused by high-pri
Janssen's antidepressant Spravato (esketamine) has failed to demonstrate efficacy in clinical trials in China following Japan, raising questions about its effectiveness in Koreans.The Central Pharmaceutical Review Committee under the Ministry of Food and Drug Safety (MFDS) concluded that the drugmak
More than seven months have passed since MSD Korea’s application for expanding coverage for 13 indications of Keytruda (pembrolizumab) was stuck in the Cancer Disease Review Committee (CDRC), prompting anxious patients to request the review of individual indications.Contrary to MSD Korea's intention
Enhertu (trastuzumab deruxtecan), a next-generation antibody-drug conjugate (ADC) developed by Daiichi Sankyo, recently passed the Pharmaceutical Reimbursement Evaluation Committee (PREC)'s deliberations, moving closer toward health insurance coverage.On Thursday, the Health Insurance Review and Ass
Once a year, leading medical experts in aesthetics worldwide convene to examine beauty trends, delve into the medico-scientific contributions that medical aesthetics can offer patients, and articulate their vision for elevating the quality of life. The Merz Aesthetics Expert Summit (MEXS) stands as